Pacira | PCRX - Selling And Administration Expenses


Pacira reported $83.88M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Assertio Holdings USD 16.73M 1.66M Sep/2024
Astellas Pharma JPY 234.7B 12.92B Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.03B 719M Mar/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025
Xoma USD 11M 2.54M Jun/2024
Zoetis USD 588M 31M Mar/2026